Watson Pharmaceuticals Receives FDA Approval For Generic Razadyne® ER Capsules

Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, recently announced that its subsidiary, Watson Laboratories, Inc., has received approval recently from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for galantamine hydrobromide extended-release capsules, eq. to 8 mg, 16 mg and 24 mg (galantamine base). Galantamine hydrobromide extended-release capsules are the generic equivalent to Ortho McNeil Janssen's Razadyne® ER, galantamine HBr extended-release capsules, which are indicated for the treatment of Alzheimer's disease. Watson intends to launch the product immediately. Razadyne® ER had annual sales of approximately $112M for the twelve months ending September 2008, according to IMS sales data.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses. For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com/.

SOURCE: Watson Pharmaceuticals, Inc.